The Supreme Court orders the Centre to set up a panel to regulate “unethical” marketing practices by pharmaceutical companies. The petition before the court alleges that some firms use incentives to influence doctors’ prescribing behaviour, including expensive gifts and overseas trips.
Multiple outlets report that the matter has been before the top court for several years and has drawn repeated judicial attention. Coverage notes that the court’s direction is aimed at addressing promotional activities that raise concerns about conflicts of interest in healthcare decision-making. While outlets differ slightly in emphasis, they agree on the core development: the court directs the government to create a regulatory mechanism or oversight panel to curb the alleged practices.
The reports frame the order as part of the court’s ongoing scrutiny of pharmaceutical marketing conduct, reflecting concerns that current practices may undermine prescribing independence. The next steps and specific structure or mandate of the panel are not detailed consistently across the accounts, but the directive to constitute it is common to all sources.
